Our Development organization oversees the development of new medicines discovered by our researchers and partners.
This division is responsible for advancing our pipeline of investigational medicines, to bring transformative new treatment options to patients with serious diseases. It leads the clinical development of potential new medicines, running large clinical trials and generating evidence that turns molecules to medicines. It has key hubs in Switzerland (Basel), the USA (East Hanover) and India (Hyderabad and Mumbai).
The India hub has evolved over 20 years and today sees three vibrant state-of-the-art centres across two cities, Hyderabad - at the Novartis Corporate Center (NOCC) and Genome Valley, and a recent one in Mumbai. Today, the India hub is an important base to support the development journey of many breakthrough medicines across all therapy areas (cardiovascular, oncology, immunology, neurology and global health). The India center supports all global functions including Global Clinical Operations, Technical R&D, Patient Safety and Pharmacovigilance, Regulatory Affairs, Advanced Quantitative Sciences, to name a few.
The vast footprint of the Development division in India (~2,400 employees) is instrumental in supporting the company’s long-term growth and delivering on its purpose to improve and extend people’s lives.
For the last 12+ years, Novartis Technical R&D has been increasing its footprint in Genome Valley, Hyderabad and currently 350+ scientists including Masters, PhDs and post doctorates are supporting to the pharmaceutical development of new chemical entities.
As India is cementing its position as a destination of choice, the hub is providing impetus to bright leaders and also deepening its focus on drug development work. The Development Hub today* has:
